Stack Creep

Stack Creep is the gradual expansion of a supplement routine until the routine itself becomes the intervention, even when the evidence, endpoints, and owners are unclear.

Also known as: supplement sprawl, protocol drift, pill-stack bloat, supplement accretion

Context

Longevity nutrition creates a perfect opening for accumulation. One capsule is added after a podcast episode. Another follows a lab result. A third appears because a molecule touches AMPK, mTOR, NAD+, inflammation, methylation, glucose, sleep, or mitochondrial function. None of those reasons is absurd by itself. The problem is the sequence.

Over months and years, a person can move from a multivitamin and vitamin D to a bathroom shelf with 15, 25, or 40 products. The public limit case is Bryan Johnson’s roughly 100-pill Blueprint-style stack, backed by a highly measured personal protocol and substantial staff support. The working case is less theatrical: half-used bottles, subscriptions that keep arriving, powders with overlapping ingredients, and no clear record of why each item is still there.

Stack Creep is not the same as clinician-directed correction of a documented deficiency. Iron deficiency, vitamin B12 deficiency, vitamin D deficiency, pregnancy-related folate needs, malabsorption, post-bariatric surgery supplementation, and diagnosed medical conditions can make targeted supplementation medically ordinary. The antipattern begins when addition becomes the default, subtraction disappears, and the reader no longer knows which items earn their place.

Problem

Each supplement is easier to justify at the moment of addition than the whole stack is to defend a year later. The evidence is usually assessed one item at a time: a small trial, a plausible mechanism, an observational association, an expert’s protocol, or a biomarker story. The combined system is rarely tested.

That creates an opaque interaction profile. A single item may be low risk. Ten items can overlap in dose, affect medications, complicate surgery planning, alter lab interpretation, raise bleeding risk, irritate the gastrointestinal tract, or make it harder to identify what caused a symptom. Cost also becomes less visible. A $25 bottle is trivial. A recurring stack can become a $200 to $800 monthly habit before anyone has asked what endpoint it changed.

The deeper failure is outsourced judgment. The stack becomes a borrowed protocol from a clinician, influencer, forum, brand, or public self-experimenter. The reader may feel sophisticated because every item has a rationale. But if the rationale, dose, endpoint, and stopping rule aren’t written down, the system is mostly belief with inventory.

Forces

• Mechanism language makes weak claims feel precise before human outcome data exist.
• Adding a supplement feels active, while subtracting one feels like losing protection.
• The cost of each item is small enough to escape scrutiny, but the stack cost is not.
• Supplement regulation leaves more responsibility on the buyer than many readers assume.
• A product can be useful for a documented indication and still be unjustified as a permanent longevity default.
• Personality protocols reward copying visible complexity rather than copying the measurement discipline behind them.
• Clinicians can miss interaction risks when patients don’t disclose the full supplement list.

Solution

Replace stack logic with an item-by-item ledger and a subtraction review. The corrective frame is not a better stack list. It is a habit of making every item answer the same questions.

The ledger changes the burden of proof. A supplement can remain because it corrects a deficiency, supports a clinician-directed plan, has a clean endpoint, or carries low cost and low interaction risk for a clearly bounded experiment. It should not remain because “it might help” was once plausible and no one revisited the decision.

The strongest version of the audit borrows a habit from medication review without pretending supplements are prescription drugs. Periodically, each item has to re-earn its place. Some items will pass easily. Others will be exposed as duplicates, expired experiments, old responses to a lab value that has normalized, or speculative add-ons that no one owns.

This is also where basic nutrition gets priority. Mediterranean Diet Pattern, Protein Intake for Sarcopenia Prevention, and food-level Polyphenol Intake often answer more durable questions than another capsule. A stack that grows while diet quality, protein adequacy, resistance training, sleep, and medication disclosure remain thin is not advanced. It is poorly governed.

Evidence

Evidence tier: Observational (human, large) for supplement prevalence and adverse-event surveillance; mixed evidence by individual supplement and endpoint. Stack Creep is a named failure mode, not a clinical diagnosis. The evidence comes from prevalence, regulation, adverse-event data, and preventive-supplement trials that show why accumulation deserves skepticism.

Supplement use is common enough that this is not a fringe problem. Kantor and colleagues analyzed National Health and Nutrition Examination Survey data from 1999 to 2012 and found that about 52% of US adults reported using at least one supplement in the prior 30 days in both the 1999-2000 and 2011-2012 cycles. The pattern changed beneath that stable headline: multivitamin and multimineral use fell, while vitamin D and fish oil rose substantially (Kantor et al., 2016). That is exactly the soil Stack Creep grows in: products rotate with the culture, while the habit of adding remains.

The preventive-outcome evidence is much thinner than the market implies. In 2022, the US Preventive Services Task Force concluded that evidence was insufficient for multivitamins and most single or paired nutrients for primary prevention of cardiovascular disease or cancer in community-dwelling, nonpregnant adults. It recommended against beta carotene and vitamin E for those endpoints (USPSTF, 2022). That finding doesn’t mean every supplement is useless. It means broad preventive claims need more restraint than stack culture usually gives them.

The regulatory structure also matters. The FDA generally does not approve dietary supplements for safety or effectiveness before marketing, and manufacturers are responsible for ensuring products comply with the law. The FTC’s health-products guidance states that health-related advertising claims require competent and reliable scientific evidence, often human clinical testing depending on the claim. Those standards are stricter than the informal language used in many supplement discussions.

Safety is not only theoretical. Geller and colleagues used a nationally representative sample of 63 emergency departments from 2004 to 2013 and estimated about 23,000 US emergency department visits per year, with about 2,000 hospitalizations, related to dietary supplement adverse events. Many events involved weight-loss and energy products; in adults aged 65 and older, swallowing problems from micronutrient pills were a notable source of visits (Geller et al., 2015).

The NIH Office of Dietary Supplements gives the practical implication: supplements can interact with medicines, affect surgery and anesthesia, raise bleeding concerns, and change how clinicians interpret health events. It also advises keeping a complete list and sharing it with health-care providers. Stack Creep is what happens when that list exists physically on a shelf but not cognitively as a reviewed plan.

How It Plays Out

A 48-year-old longevity reader starts with vitamin D after a low lab value. That item has a clean indication and a clinician can recheck the endpoint. Then magnesium is added for sleep, fish oil for cardiovascular risk, creatine for training, curcumin for inflammation, berberine after a glucose thread, glycine after a podcast, collagen for joints, and a mixed “mitochondrial” product because the pathway sounds relevant. A year later, the original vitamin D decision is still defensible. The stack around it is not clearly owned.

A 67-year-old brings a medication list to a primary-care visit but leaves out supplements because they don’t feel like medicines. The clinician sees an anticoagulant, upcoming dental surgery, and normal liver enzymes, but not the high-dose fish oil, garlic extract, turmeric blend, sleep product, and green-tea extract. No one has to assume catastrophe for the system to be weak. The relevant people are making decisions from an incomplete list.

A performance-focused reader uses a biological-age test every quarter and adds a new supplement whenever the score disappoints. The test gives a sense of feedback, but the inputs are too many to interpret. Was the change sleep, training load, weight loss, inflammation, lab variability, supplement timing, or the test itself? Biological Age can be useful as a concept, but it becomes a poor owner for an unstructured stack.

The Bryan Johnson-style protocol is different because it is unusually documented, measured, and resourced. That makes it interesting as an observed self-experiment. It doesn’t make the pill count transferable. Copying the visible stack without copying the measurement system, clinical review, adverse-event tracking, and willingness to revise turns a public protocol into Lifestyle Theater.

Consequences

Benefits. Naming Stack Creep protects per-supplement discussion from reading as endorsement. A reader can learn about creatine, vitamin D, omega-3s, magnesium, polyphenols, or NAD-adjacent compounds without converting every plausible item into a permanent purchase.

The audit also recovers money and attention. A $300 monthly stack is not automatically wasteful, but it has to compete with food quality, resistance training, sleep support, dental care, blood-pressure management, ApoB follow-up, coaching, and time. The ledger makes those tradeoffs visible.

It also improves clinical communication. A complete supplement list can change how a clinician thinks about bleeding risk, liver enzymes, kidney function, palpitations, gastrointestinal symptoms, sleepiness, surgery planning, pregnancy or nursing, and drug interactions.

Liabilities. The correction can slide into supplement nihilism. That is too crude. Some supplements have clear roles in documented deficiency, pregnancy-related folate needs, diagnosed conditions, restricted diets, malabsorption, older-adult nutrition, sports nutrition, and clinician-directed care. The antipattern is accumulation without governance, not supplementation itself.

The audit can also create false precision. A ledger doesn’t prove efficacy. It only makes the decision legible enough to review. Some endpoints are subjective, some trials are short, and some risks are not known until a product is used widely. The right posture is disciplined uncertainty: fewer permanent assumptions, more explicit ownership, and no shame in removing what no longer has a job.

Related Patterns

Sources

• Kantor, Elizabeth D., Colin D. Rehm, Mengmeng Du, Emily White, and Edward L. Giovannucci. “Trends in Dietary Supplement Use Among US Adults From 1999-2012.” JAMA 316, no. 14 (2016): 1464-1474.
• Geller, Andrew I., Nadine Shehab, Neal J. Weidle, Mary C. Lovegrove, Benjamin J. Wolpert, Babgaleh B. Timbo, et al. “Emergency Department Visits for Adverse Events Related to Dietary Supplements.” New England Journal of Medicine 373 (2015): 1531-1540.
• US Preventive Services Task Force. “Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement.” JAMA 327, no. 23 (2022): 2326-2333.
• US Food and Drug Administration. “Questions and Answers on Dietary Supplements.” Content current as of February 21, 2024.
• NIH Office of Dietary Supplements. “Dietary Supplements: What You Need to Know.” Updated January 4, 2023.
• Federal Trade Commission. “Health Products Compliance Guidance.” December 2022.
• Hung, Anna, Yoon Hie Kim, and Juliessa M. Pavon. “Deprescribing in Older Adults with Polypharmacy.” BMJ 385 (2024): e074892.

Medical and Legal Boundary

This entry is a reference, not medical advice. It describes published evidence, regulatory status, and common clinical practice patterns. It does not diagnose, prescribe, or replace a clinician’s judgment for a specific person.

Supplement decisions that intersect with prescription medications, diagnosed medical conditions, pregnancy, nursing, surgery, anticoagulant or antiplatelet therapy, liver disease, kidney disease, cancer treatment, eating-disorder history, frailty, unexplained weight loss, or a documented deficiency require qualified clinical supervision. Clinician-directed supplementation for a measured deficiency or medical indication is different from Stack Creep.